Economic Evaluation and Cost-Effectiveness Thresholds: Signals to Firms and Implications for R&D Investment and Innovation

Author： Vernon John A.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.27, Iss.10, 2009-10, pp. : 797-806

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Economic and Cost-Effectiveness Considerations for Pharmacogenetics Tests: An Integral Part of Translational Research and Innovation Uptake in Personalized Medicine

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 7, Iss. 4, 2009-12 ,pp. : 284-296

Bentham Science Publishers

Access to resources Recommend Favorite

Economic Evaluation of Treatment Options in Patients with Alzheimer's Disease: A Systematic Review of Cost-Effectiveness Analyses

By Pouryamout Laura  

Drugs, Vol. 72, Iss. 6, 2012-04 ,pp. : 789-802

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Schizophrenia Relapse Prevention: An Economic Evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) Study in Spain

By Bernardo Miguel  

Clinical Drug Investigation, Vol. 26, Iss. 8, 2006-01 ,pp. : 447-457

Adis International

Access to resources Recommend Favorite

Irrelevance of explicit cost-effectiveness thresholds when coverage decisions can be reversed

By Basu Anirban  

Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 13, Iss. 2, 2013-04 ,pp. : 163-165

Informa Healthcare

Access to resources Recommend Favorite

Balancing cost effectiveness and innovation

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 531, 2007-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite